Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.57 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892131 | 0.89 | APP (0.74) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL31286465 | 0.85 | APP (0.70) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL13062756 | 0.84 | APP (0.68) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL13062755 | 0.84 | APP (0.68) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL2061418 | 0.84 | APP (1.00) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL12974135 | 0.84 | APP (1.00) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL14199907 | 0.84 | APP (1.00) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL5429982 | 0.84 | APP (0.83) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL2633246 | 0.83 | MAPT (0.71) | APPGLAGAASNCA | |
| SCHEMBL1572797 | 0.81 | APP (0.74) | APPGLAGAASULT1A1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095235-A1 | THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-04-19 | — | — | US | disclosed |
| US-20110257407-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH | 2011-10-20 | — | — | US | disclosed |
| US-7854920-B2 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | UNIVERSITY OF PITTSBURGH (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH | 2008-06-26 | — | — | US | disclosed |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | UNIVERSITY OF PITTSBURGH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095235-A1 | THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, MAPT, PSEN2 | APP 1/4885GLA 138/4885GAA 1020/4885 |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885GLA 189/4885GAA 986/4885 |
| US-20110257407-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | APP 1/4885GLA 180/4885GAA 962/4885 |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | APOL1, APOB, APP | APP 3/4885GLA 806/4885GAA 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.